Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 4/20 | 0.32 |
| ▸ | HRH1 | P35367 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386750 | 1.00 | CCR5 (0.33) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3383779 | 0.87 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3354631 | 0.87 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3383782 | 0.87 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3352307 | 0.87 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3352854 | 0.81 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL3357087 | 0.81 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL13387530 | 0.81 | CTSK (0.36) | CCR5CTSKKCNA3MAOAMAOB | |
| SCHEMBL621767 | 0.76 | KCNA3 (0.51) | CCR5CTSKKCNA3CA1CA2 | |
| SCHEMBL4436916 | 0.76 | CTSK (0.38) | CTSKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB | 2012-10-25 | — | — | US | disclosed |
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2121702-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | CCR5 1437/4885CTSK 512/4885KCNA3 1598/4885 |
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | CCR5 1437/4885CTSK 512/4885KCNA3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.